Key result
New-generation antiseizure medications such as levetiracetam and lamotrigine are preferred for post-stroke epilepsy due to high tolerability and low interaction potential with direct oral anticoagulants.
Answers are grounded in this paper and cite their sources.
This commentary and review challenges the blanket contraindication of levetiracetam and several other antiepileptic drugs with NOACs in the 2018 EHRA guide due to lack of human clinical interaction evidence, while outlining personalized management and novel biomarker strategies for post-stroke seizures and epilepsy.
This commentary refers to ‘The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation’, by J. Steffel et al., on page 1330. We read with great interest the article by Steffel et al.1 as neurology specialists. The authors performed a very useful and comprehensive guide. However, in table 5 carbamazepine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproic acid have been marked with hatched dark brown, and have been reported to be contraindicated due to their effects on plasma levels of NOACs. It has been emphasized that ‘the hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC, where available or expert opinion’.1 As mentioned in the articles2 , 3 that the authors used as reference for the table 5, the clinical relevance of these drug interactions is largely unknown since mainly data from in vitro and animal studies are available, and there are only sporadic case reports in humans. Since there are indications that substrate recognition and transport efficacy of p-gp differs between human and mouse for certain antiepileptic drugs, the results of animal studies should be very careful when adapting to human beings. In the reference cited by the authors, Stollberger and Finsterer3 recommended that carbamazepine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproic acid should be avoided, not to be contraindicated. Moreover, even in the animal study on which this recommendation was based, Moerman et al.4 reported that in vitro interaction studies between highly permeable compounds, such as most antiepileptic drugs (AEDs) and P-gp might be doubtful, and cell lines often express P-gp in amounts that by far exceed those observed in vivo which might lead to exaggerated expectations regarding in vivo effects. Previous stroke responsible for 30–40% of all cases of epilepsy in the elderly. Most of these patients require long-term AEDs treatment.3 The clinicians do not have much choice due to the comorbidity of the patients and other medications used. In daily practice, Neurologists sometimes have to use NOAC and AEDs together. Therefore, without clear and convincing evidence, we think the statement of ‘contraindicated due to reduced NOAC plasma levels’ is inappropriate. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Kurt et al. (2019) conducted a review in Post-stroke seizures, post-stroke epilepsy, and atrial fibrillation requiring anticoagulation. Non-vitamin K antagonist oral anticoagulants combined with antiepileptic drugs (antiseizure medications) was evaluated. New-generation antiseizure medications such as levetiracetam and lamotrigine are preferred for post-stroke epilepsy due to high tolerability and low interaction potential with direct oral anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: